Immunomodulation through Nutrition Should Be a Key Trend in Type 2 Diabetes Treatment
Abstract
:1. Introduction
2. Methods
2.1. Search Strategy and Sample Period
2.2. Selection Criteria
3. Pathogenesis of Diabetes with Particular Emphasis on the Role of the Immune System
4. Novel Therapeutic Options in the Treatment of Type 2 Diabetes
4.1. Tirzepatide
4.2. Thiazolidinediones
4.3. GPCR119 Receptor
4.4. Vaspin
4.5. Metrnl
4.6. Fetuin-A
5. The Role of Immunomodulation through Nutrition as a Key Therapeutic Strategy in Patients with Diabetes
5.1. Macroelements
5.1.1. Magnesium
5.1.2. Calcium
5.1.3. Potassium
5.1.4. Sodium
5.1.5. Phosphorus
5.1.6. Sulfur
5.2. Microelements
5.2.1. Zinc
5.2.2. Selenium
5.2.3. Iron
5.2.4. Iodine
5.2.5. Copper
5.2.6. Cobalt
5.2.7. Chrome
5.2.8. Manganese
5.2.9. Molybdenum
5.2.10. Silicon
5.3. Vitamins
5.3.1. Vitamin D
5.3.2. Vitamin E
5.3.3. Vitamin C
5.3.4. B vitamins
Vitamin B1
Vitamin B6
Vitamin B12
Folic Acid
5.4. Selected Substances with Immunomodulatory Effects
5.4.1. Coenzyme Q10 (CoQ10)
5.4.2. Alpha-Lipoic Acid
5.4.3. Omega-3 Fatty Acids
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Ong, K.L.; Stafford, L.K.; McLaughlin, S.A.; Boyko, E.J.; Vollset, S.E.; Smith, A.E.; Dalton, B.E.; Duprey, J.; Cruz, J.A.; Hagins, H.; et al. Global, Regional, and National Burden of Diabetes from 1990 to 2021, with Projections of Prevalence to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021. Lancet 2023, 402, 203–234. [Google Scholar] [CrossRef]
- Magliano, D.; Boyko, E.J. IDF Diabetes Atlas, 10th ed.; International Diabetes Federation: Brussels, Belgium, 2021; ISBN 978-2-930229-98-0. [Google Scholar]
- Zheng, Y.; Ley, S.H.; Hu, F.B. Global Aetiology and Epidemiology of Type 2 Diabetes Mellitus and Its Complications. Nat. Rev. Endocrinol. 2018, 14, 88–98. [Google Scholar] [CrossRef] [PubMed]
- Cole, J.B.; Florez, J.C. Genetics of Diabetes Mellitus and Diabetes Complications. Nat. Rev. Nephrol. 2020, 16, 377–390. [Google Scholar] [CrossRef] [PubMed]
- Wysocki, M.J.; Miller, M. Lalonde’s paradigm, World Health Organization and new public health. Przegl. Epidemiol. 2003, 57, 505–512. [Google Scholar]
- Mayer, A.-M.B.; Trenchard, L.; Rayns, F. Historical Changes in the Mineral Content of Fruit and Vegetables in the UK from 1940 to 2019: A Concern for Human Nutrition and Agriculture. Int. J. Food Sci. Nutr. 2022, 73, 315–326. [Google Scholar] [CrossRef]
- Thomas, D. A Study on the Mineral Depletion of the Foods Available to Us as a Nation over the Period 1940 to 1991. Nutr. Health 2003, 17, 85–115. [Google Scholar] [CrossRef] [PubMed]
- Hasanaliyeva, G.; Sufar, E.K.; Wang, J.; Rempelos, L.; Volakakis, N.; Iversen, P.O.; Leifert, C. Effects of Agricultural Intensification on Mediterranean Diets: A Narrative Review. Foods 2023, 12, 3779. [Google Scholar] [CrossRef]
- Wang, C.; Zhang, R.; Wei, X.; Lv, M.; Jiang, Z. Metalloimmunology: The Metal Ion-Controlled Immunity. In Advances in Immunology; Elsevier: Amsterdam, The Netherlands, 2020; Volume 145, pp. 187–241. ISBN 978-0-12-817878-2. [Google Scholar]
- Gombart, A.F.; Pierre, A.; Maggini, S. A Review of Micronutrients and the Immune System–Working in Harmony to Reduce the Risk of Infection. Nutrients 2020, 12, 236. [Google Scholar] [CrossRef]
- Grimble, R.F. Immunonutrition. Curr. Opin. Gastroenterol. 2005, 21, 216–222. [Google Scholar] [CrossRef]
- Sánchez-Guillén, L.; Arroyo, A. Immunonutrition in Patients with Colon Cancer. Immunotherapy 2020, 12, 5–8. [Google Scholar] [CrossRef]
- Berbudi, A.; Rahmadika, N.; Tjahjadi, A.I.; Ruslami, R. Type 2 Diabetes and Its Impact on the Immune System. Curr. Diabetes Rev. 2020, 16, 442–449. [Google Scholar] [CrossRef]
- Mooradian, A.D.; Reed, R.L.; Meredith, K.E.; Scuderi, P. Serum Levels of Tumor Necrosis Factor and IL-1α and IL-1β in Diabetic Patients. Diabetes Care 1991, 14, 63–65. [Google Scholar] [CrossRef]
- Reinhold, D.; Ansorge, S. Elevated Glucose Levels Stimulate Transforming Growth Factor-Β1 (TGF-Β1), Suppress Interleukin IL-2, IL-6 and IL-10 Production and DNA Synthesis in Peripheral Blood Mononuclear Cells. Horm. Metab. Res. 1996, 28, 267–270. [Google Scholar] [CrossRef] [PubMed]
- Tanaka, T.; Narazaki, M.; Kishimoto, T. IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harb. Perspect. Biol. 2014, 6, a016295. [Google Scholar] [CrossRef] [PubMed]
- Kumar, M.; Roe, K.; Nerurkar, P.V.; Orillo, B.; Thompson, K.S.; Verma, S.; Nerurkar, V.R. Reduced Immune Cell Infiltration and Increased Pro-Inflammatory Mediators in the Brain of Type 2 Diabetic Mouse Model Infected with West Nile Virus. J. Neuroinflamm. 2014, 11, 80. [Google Scholar] [CrossRef] [PubMed]
- Jafar, N.; Edriss, H.; Nugent, K. The Effect of Short-Term Hyperglycemia on the Innate Immune System. Am. J. Med. Sci. 2016, 351, 201–211. [Google Scholar] [CrossRef] [PubMed]
- Gupta, S.; Maratha, A.; Siednienko, J.; Natarajan, A.; Gajanayake, T.; Hoashi, S.; Miggin, S. Analysis of Inflammatory Cytokine and TLR Expression Levels in Type 2 Diabetes with Complications. Sci. Rep. 2017, 7, 7633. [Google Scholar] [CrossRef] [PubMed]
- Chao, W.-C.; Yen, C.-L.; Wu, Y.-H.; Chen, S.-Y.; Hsieh, C.-Y.; Chang, T.-C.; Ou, H.-Y.; Shieh, C.-C. Increased Resistin May Suppress Reactive Oxygen Species Production and Inflammasome Activation in Type 2 Diabetic Patients with Pulmonary Tuberculosis Infection. Microbes Infect. 2015, 17, 195–204. [Google Scholar] [CrossRef] [PubMed]
- Jakubczyk, K.; Dec, K.; Kałduńska, J.; Kawczuga, D.; Kochman, J.; Janda, K. Reactive Oxygen Species—Sources, Functions, Oxidative Damage. Pol. Merkur. Lek. Organ Pol. Tow. Lek. 2020, 48, 124–127. [Google Scholar]
- Darenskaya, M.A.; Kolesnikova, L.I.; Kolesnikov, S.I. Oxidative Stress: Pathogenetic Role in Diabetes Mellitus and Its Complications and Therapeutic Approaches to Correction. Bull. Exp. Biol. Med. 2021, 171, 179–189. [Google Scholar] [CrossRef]
- Luc, K.; Schramm-Luc, A.; Guzik, T.J.; Mikolajczyk, T.P. Oxidative Stress and Inflammatory Markers in Prediabetes and Diabetes. J. Physiol. Pharmacol. 2019, 70, 809–824. [Google Scholar] [CrossRef]
- Wronka, M.; Krzemińska, J.; Młynarska, E.; Rysz, J.; Franczyk, B. The Influence of Lifestyle and Treatment on Oxidative Stress and Inflammation in Diabetes. Int. J. Mol. Sci. 2022, 23, 15743. [Google Scholar] [CrossRef] [PubMed]
- Rohm, T.V.; Meier, D.T.; Olefsky, J.M.; Donath, M.Y. Inflammation in Obesity, Diabetes, and Related Disorders. Immunity 2022, 55, 31–55. [Google Scholar] [CrossRef] [PubMed]
- Ying, W.; Riopel, M.; Bandyopadhyay, G.; Dong, Y.; Birmingham, A.; Seo, J.B.; Ofrecio, J.M.; Wollam, J.; Hernandez-Carretero, A.; Fu, W.; et al. Adipose Tissue Macrophage-Derived Exosomal miRNAs Can Modulate In Vivo and In Vitro Insulin Sensitivity. Cell 2017, 171, 372–384.e12. [Google Scholar] [CrossRef] [PubMed]
- ElSayed, N.A.; Aleppo, G.; Aroda, V.R.; Bannuru, R.R.; Brown, F.M.; Bruemmer, D.; Collins, B.S.; Cusi, K.; Das, S.R.; Gibbons, C.H.; et al. Introduction and Methodology: Standards of Care in Diabetes—2023. Diabetes Care 2023, 46, S5–S9. [Google Scholar] [CrossRef] [PubMed]
- Forzano, I.; Varzideh, F.; Avvisato, R.; Jankauskas, S.S.; Mone, P.; Santulli, G. Tirzepatide: A Systematic Update. Int. J. Mol. Sci. 2022, 23, 14631. [Google Scholar] [CrossRef] [PubMed]
- Nowak, M.; Nowak, W.; Grzeszczak, W. Tirzepatide—A Dual GIP/GLP-1 Receptor Agonist—A New Antidiabetic Drug with Potential Metabolic Activity in the Treatment of Type 2 Diabetes. Endokrynol. Pol. 2022, 73, 745–755. [Google Scholar] [CrossRef] [PubMed]
- Nauck, M.A.; Quast, D.R.; Wefers, J.; Pfeiffer, A.F.H. The Evolving Story of Incretins (GIP and GLP-1) in Metabolic and Cardiovascular Disease: A Pathophysiological Update. Diabetes Obes. Metab. 2021, 23 (Suppl. S3), 5–29. [Google Scholar] [CrossRef]
- Nauck, M.A.; Müller, T.D. Incretin Hormones and Type 2 Diabetes. Diabetologia 2023, 66, 1780–1795. [Google Scholar] [CrossRef]
- Kim, S.-J.; Nian, C.; McIntosh, C.H.S. GIP Increases Human Adipocyte LPL Expression through CREB and TORC2-Mediated Trans-Activation of the LPL Gene. J. Lipid Res. 2010, 51, 3145–3157. [Google Scholar] [CrossRef]
- Baggio, L.L.; Drucker, D.J. Biology of Incretins: GLP-1 and GIP. Gastroenterology 2007, 132, 2131–2157. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Q.; Delessa, C.T.; Augustin, R.; Bakhti, M.; Colldén, G.; Drucker, D.J.; Feuchtinger, A.; Caceres, C.G.; Grandl, G.; Harger, A.; et al. The Glucose-Dependent Insulinotropic Polypeptide (GIP) Regulates Body Weight and Food Intake via CNS-GIPR Signaling. Cell Metab. 2021, 33, 833–844.e5. [Google Scholar] [CrossRef] [PubMed]
- Zhao, F.; Zhang, C.; Zhou, Q.; Hang, K.; Zou, X.; Chen, Y.; Wu, F.; Rao, Q.; Dai, A.; Yin, W.; et al. Structural Insights into Hormone Recognition by the Human Glucose-Dependent Insulinotropic Polypeptide Receptor. eLife 2021, 10, e68719. [Google Scholar] [CrossRef]
- Sun, B.; Willard, F.S.; Feng, D.; Alsina-Fernandez, J.; Chen, Q.; Vieth, M.; Ho, J.D.; Showalter, A.D.; Stutsman, C.; Ding, L.; et al. Structural Determinants of Dual Incretin Receptor Agonism by Tirzepatide. Proc. Natl. Acad. Sci. USA 2022, 119, e2116506119. [Google Scholar] [CrossRef] [PubMed]
- Frías, J.P. Tirzepatide: A Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Dual Agonist in Development for the Treatment of Type 2 Diabetes. Expert Rev. Endocrinol. Metab. 2020, 15, 379–394. [Google Scholar] [CrossRef] [PubMed]
- Heise, T.; DeVries, J.H.; Urva, S.; Li, J.; Pratt, E.J.; Thomas, M.K.; Mather, K.J.; Karanikas, C.A.; Dunn, J.; Haupt, A.; et al. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People with Type 2 Diabetes. Diabetes Care 2023, 46, 998–1004. [Google Scholar] [CrossRef] [PubMed]
- Del Prato, S.; Kahn, S.E.; Pavo, I.; Weerakkody, G.J.; Yang, Z.; Doupis, J.; Aizenberg, D.; Wynne, A.G.; Riesmeyer, J.S.; Heine, R.J.; et al. Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4): A Randomised, Open-Label, Parallel-Group, Multicentre, Phase 3 Trial. Lancet 2021, 398, 1811–1824. [Google Scholar] [CrossRef] [PubMed]
- Willard, F.S.; Douros, J.D.; Gabe, M.B.N.; Showalter, A.D.; Wainscott, D.B.; Suter, T.M.; Capozzi, M.E.; Van Der Velden, W.J.C.; Stutsman, C.; Cardona, G.R.; et al. Tirzepatide Is an Imbalanced and Biased Dual GIP and GLP-1 Receptor Agonist. JCI Insight 2020, 5, e140532. [Google Scholar] [CrossRef] [PubMed]
- Fisman, E.Z.; Tenenbaum, A. The Dual Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Tirzepatide: A Novel Cardiometabolic Therapeutic Prospect. Cardiovasc. Diabetol. 2021, 20, 225. [Google Scholar] [CrossRef]
- Sinha, R.; Papamargaritis, D.; Sargeant, J.A.; Davies, M.J. Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. J. Obes. Metab. Syndr. 2023, 32, 25–45. [Google Scholar] [CrossRef]
- Lebovitz, H.E. Thiazolidinediones: The Forgotten Diabetes Medications. Curr. Diabetes Rep. 2019, 19, 151. [Google Scholar] [CrossRef] [PubMed]
- Alhowail, A.; Alsikhan, R.; Alsaud, M.; Aldubayan, M.; Rabbani, S.I. Protective Effects of Pioglitazone on Cognitive Impairment and the Underlying Mechanisms: A Review of Literature. Drug Des. Dev. Ther. 2022, 16, 2919–2931. [Google Scholar] [CrossRef] [PubMed]
- Holm, L.J.; Mønsted, M.Ø.; Haupt-Jorgensen, M.; Buschard, K. PPARs and the Development of Type 1 Diabetes. PPAR Res. 2020, 2020, 6198628. [Google Scholar] [CrossRef] [PubMed]
- Menendez-Gutierrez, M.P.; Roszer, T.; Ricote, M. Biology and Therapeutic Applications of Peroxisome Proliferator—Activated Receptors. Curr. Top. Med. Chem. 2012, 12, 548–584. [Google Scholar] [CrossRef]
- Odegaard, J.I.; Ricardo-Gonzalez, R.R.; Goforth, M.H.; Morel, C.R.; Subramanian, V.; Mukundan, L.; Eagle, A.R.; Vats, D.; Brombacher, F.; Ferrante, A.W.; et al. Macrophage-Specific PPARγ Controls Alternative Activation and Improves Insulin Resistance. Nature 2007, 447, 1116–1120. [Google Scholar] [CrossRef] [PubMed]
- Le Menn, G.; Neels, J. Regulation of Immune Cell Function by PPARs and the Connection with Metabolic and Neurodegenerative Diseases. Int. J. Mol. Sci. 2018, 19, 1575. [Google Scholar] [CrossRef] [PubMed]
- Holm, L.J.; Krogvold, L.; Hasselby, J.P.; Kaur, S.; Claessens, L.A.; Russell, M.A.; Mathews, C.E.; Hanssen, K.F.; Morgan, N.G.; Koeleman, B.P.C.; et al. Abnormal Islet Sphingolipid Metabolism in Type 1 Diabetes. Diabetologia 2018, 61, 1650–1661. [Google Scholar] [CrossRef] [PubMed]
- Janani, C.; Ranjitha Kumari, B.D. PPAR Gamma Gene—A Review. Diabetes Metab. Syndr. Clin. Res. Rev. 2015, 9, 46–50. [Google Scholar] [CrossRef] [PubMed]
- Tontonoz, P.; Spiegelman, B.M. Fat and Beyond: The Diverse Biology of PPARγ. Annu. Rev. Biochem. 2008, 77, 289–312. [Google Scholar] [CrossRef]
- Lebovitz, H.E. Insulin Resistance and Its Treatment by Thiazolidinediones. Recent Prog. Horm. Res. 2001, 56, 265–294. [Google Scholar] [CrossRef]
- Holland, W.L.; Miller, R.A.; Wang, Z.V.; Sun, K.; Barth, B.M.; Bui, H.H.; Davis, K.E.; Bikman, B.T.; Halberg, N.; Rutkowski, J.M.; et al. Receptor-Mediated Activation of Ceramidase Activity Initiates the Pleiotropic Actions of Adiponectin. Nat. Med. 2011, 17, 55–63. [Google Scholar] [CrossRef] [PubMed]
- Straub, L.G.; Scherer, P.E. Metabolic Messengers: Adiponectin. Nat. Metab. 2019, 1, 334–339. [Google Scholar] [CrossRef] [PubMed]
- Nesto, R.W.; Bell, D.; Bonow, R.O.; Fonseca, V.; Grundy, S.M.; Horton, E.S.; Le Winter, M.; Porte, D.; Semenkovich, C.F.; Smith, S.; et al. Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement from the American Heart Association and American Diabetes Association. Circulation 2003, 108, 2941–2948. [Google Scholar] [CrossRef] [PubMed]
- Van Der Meer, R.W.; Rijzewijk, L.J.; De Jong, H.W.A.M.; Lamb, H.J.; Lubberink, M.; Romijn, J.A.; Bax, J.J.; De Roos, A.; Kamp, O.; Paulus, W.J.; et al. Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients with Well-Controlled Type 2 Diabetes Mellitus. Circulation 2009, 119, 2069–2077. [Google Scholar] [CrossRef] [PubMed]
- DeFronzo, R.A. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes 2009, 58, 773–795. [Google Scholar] [CrossRef] [PubMed]
- Bays, H.; Mandarino, L.; DeFronzo, R.A. Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach. J. Clin. Endocrinol. Metab. 2004, 89, 463–478. [Google Scholar] [CrossRef] [PubMed]
- Coletta, D.K.; Sriwijitkamol, A.; Wajcberg, E.; Tantiwong, P.; Li, M.; Prentki, M.; Madiraju, M.; Jenkinson, C.P.; Cersosimo, E.; Musi, N.; et al. Pioglitazone Stimulates AMP-Activated Protein Kinase Signalling and Increases the Expression of Genes Involved in Adiponectin Signalling, Mitochondrial Function and Fat Oxidation in Human Skeletal Muscle in Vivo: A Randomised Trial. Diabetologia 2009, 52, 723–732. [Google Scholar] [CrossRef]
- De Jong, M.; Van Der Worp, H.B.; Van Der Graaf, Y.; Visseren, F.L.J.; Westerink, J. Pioglitazone and the Secondary Prevention of Cardiovascular Disease. A Meta-Analysis of Randomized-Controlled Trials. Cardiovasc. Diabetol. 2017, 16, 134. [Google Scholar] [CrossRef]
- Yen, C.-L.; Wu, C.-Y.; Tsai, C.-Y.; Lee, C.-C.; Li, Y.-J.; Peng, W.-S.; Liu, J.-R.; Liu, Y.-C.; Jenq, C.-C.; Yang, H.-Y.; et al. Pioglitazone Reduces Cardiovascular Events and Dementia but Increases Bone Fracture in Elderly Patients with Type 2 Diabetes Mellitus: A National Cohort Study. Aging 2023, 15, 2721–2733. [Google Scholar] [CrossRef]
- Dhankhar, S.; Chauhan, S.; Mehta, D.K.; Nitika; Saini, K.; Saini, M.; Das, R.; Gupta, S.; Gautam, V. Novel Targets for Potential Therapeutic Use in Diabetes Mellitus. Diabetol. Metab. Syndr. 2023, 15, 17. [Google Scholar] [CrossRef]
- Pola, S.; Shah, S.R.; Pingali, H.; Zaware, P.; Thube, B.; Makadia, P.; Patel, H.; Bandyopadhyay, D.; Rath, A.; Giri, S.; et al. Discovery of a Potent G-Protein-Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes. Bioorg. Med. Chem. 2021, 35, 116071. [Google Scholar] [CrossRef] [PubMed]
- Weiner, J.; Zieger, K.; Pippel, J.; Heiker, J.T. Molecular Mechanisms of Vaspin Action—From Adipose Tissue to Skin and Bone, from Blood Vessels to the Brain. In Protein Reviews—Purinergic Receptors; Atassi, M.Z., Ed.; Advances in Experimental Medicine and Biology; Springer International Publishing: Cham, Switzerland, 2018; Volume 1111, pp. 159–188. ISBN 978-3-030-14338-1. [Google Scholar]
- Miao, Z.; Hu, W.; Li, Z.; Miao, C. Involvement of the Secreted Protein Metrnl in Human Diseases. Acta Pharmacol. Sin. 2020, 41, 1525–1530. [Google Scholar] [CrossRef] [PubMed]
- Roshanzamir, F.; Miraghajani, M.; Rouhani, M.H.; Mansourian, M.; Ghiasvand, R.; Safavi, S.M. The Association between Circulating Fetuin-A Levels and Type 2 Diabetes Mellitus Risk: Systematic Review and Meta-Analysis of Observational Studies. J. Endocrinol. Investig. 2018, 41, 33–47. [Google Scholar] [CrossRef] [PubMed]
- Mok, J.X.; Ooi, J.H.; Ng, K.Y.; Koh, R.Y.; Chye, S.M. A New Prospective on the Role of Melatonin in Diabetes and Its Complications. Horm. Mol. Biol. Clin. Investig. 2019, 40, 20190036. [Google Scholar] [CrossRef] [PubMed]
- Shah, U.; Kowalski, T.J. GPR119 Agonists for the Potential Treatment of Type 2 Diabetes and Related Metabolic Disorders. In Vitamins & Hormones; Elsevier: Amsterdam, The Netherlands, 2010; Volume 84, pp. 415–448. ISBN 978-0-12-381517-0. [Google Scholar]
- Jang, Y.K.; Lee, K.M.; Jung, K.-Y.; Kang, S.K.; Pagire, S.H.; Lee, J.M.; Pagire, H.S.; Kim, K.R.; Bae, M.A.; Lee, H.; et al. Design, Synthesis, and Biological Evaluation of Aryl N-Methoxyamide Derivatives as GPR119 Agonists. Bioorg. Med. Chem. Lett. 2017, 27, 3909–3914. [Google Scholar] [CrossRef] [PubMed]
- Albrechtsen, N.J.W.; Kuhre, R.E.; Deacon, C.F.; Holst, J.J. Targeting the Intestinal L-Cell for Obesity and Type 2 Diabetes Treatment. Expert Rev. Endocrinol. Metab. 2014, 9, 61–72. [Google Scholar] [CrossRef]
- Yang, J.W.; Kim, H.S.; Choi, Y.-W.; Kim, Y.-M.; Kang, K.W. Therapeutic Application of GPR119 Ligands in Metabolic Disorders. Diabetes Obes. Metab. 2018, 20, 257–269. [Google Scholar] [CrossRef] [PubMed]
- Shah, N.; Abdalla, M.A.; Deshmukh, H.; Sathyapalan, T. Therapeutics for Type-2 Diabetes Mellitus: A Glance at the Recent Inclusions and Novel Agents under Development for Use in Clinical Practice. Ther. Adv. Endocrinol. Metab. 2021, 12, 204201882110421. [Google Scholar] [CrossRef] [PubMed]
- Kim, Y.; Lee, S.W.; Wang, H.; Kim, R.-H.; Park, H.K.; Lee, H.; Kang, E.S. DA-1241, a Novel GPR119 Agonist, Improves Hyperglycaemia by Inhibiting Hepatic Gluconeogenesis and Enhancing Insulin Secretion in Diabetic Mice. Diabetes Metab. J. 2022, 46, 337–348. [Google Scholar] [CrossRef]
- Kurowska, P.; Mlyczyńska, E.; Dawid, M.; Jurek, M.; Klimczyk, D.; Dupont, J.; Rak, A. Review: Vaspin (SERPINA12) Expression and Function in Endocrine Cells. Cells 2021, 10, 1710. [Google Scholar] [CrossRef]
- Dimova, R.; Tankova, T. The Role of Vaspin in the Development of Metabolic and Glucose Tolerance Disorders and Atherosclerosis. BioMed Res. Int. 2015, 2015, 823481. [Google Scholar] [CrossRef] [PubMed]
- Carrión, M.; Frommer, K.W.; Pérez-García, S.; Müller-Ladner, U.; Gomariz, R.P.; Neumann, E. The Adipokine Network in Rheumatic Joint Diseases. Int. J. Mol. Sci. 2019, 20, 4091. [Google Scholar] [CrossRef] [PubMed]
- Feng, R.; Li, Y.; Wang, C.; Luo, C.; Liu, L.; Chuo, F.; Li, Q.; Sun, C. Higher Vaspin Levels in Subjects with Obesity and Type 2 Diabetes Mellitus: A Meta-Analysis. Diabetes Res. Clin. Pract. 2014, 106, 88–94. [Google Scholar] [CrossRef] [PubMed]
- Escoté, X.; Gómez-Zorita, S.; López-Yoldi, M.; Milton-Laskibar, I.; Fernández-Quintela, A.; Martínez, J.; Moreno-Aliaga, M.; Portillo, M. Role of Omentin, Vaspin, Cardiotrophin-1, TWEAK and NOV/CCN3 in Obesity and Diabetes Development. Int. J. Mol. Sci. 2017, 18, 1770. [Google Scholar] [CrossRef] [PubMed]
- Li, Z.; Zheng, S.; Wang, P.; Xu, T.; Guan, Y.; Zhang, Y.; Miao, C. Subfatin Is a Novel Adipokine and Unlike Meteorin in Adipose and Brain Expression. CNS Neurosci. Ther. 2014, 20, 344–354. [Google Scholar] [CrossRef] [PubMed]
- Li, Z.; Fan, M.; Zhang, S.; Qu, Y.; Zheng, S.; Song, J.; Miao, C. Intestinal Metrnl Released into the Gut Lumen Acts as a Local Regulator for Gut Antimicrobial Peptides. Acta Pharmacol. Sin. 2016, 37, 1458–1466. [Google Scholar] [CrossRef] [PubMed]
- Li, Z.-Y.; Song, J.; Zheng, S.-L.; Fan, M.-B.; Guan, Y.-F.; Qu, Y.; Xu, J.; Wang, P.; Miao, C.-Y. Adipocyte Metrnl Antagonizes Insulin Resistance Through PPARγ Signaling. Diabetes 2015, 64, 4011–4022. [Google Scholar] [CrossRef] [PubMed]
- Ushach, I.; Burkhardt, A.M.; Martinez, C.; Hevezi, P.A.; Gerber, P.A.; Buhren, B.A.; Schrumpf, H.; Valle-Rios, R.; Vazquez, M.I.; Homey, B.; et al. METEORIN-LIKE Is a Cytokine Associated with Barrier Tissues and Alternatively Activated Macrophages. Clin. Immunol. 2015, 156, 119–127. [Google Scholar] [CrossRef] [PubMed]
- Dadmanesh, M.; Aghajani, H.; Fadaei, R.; Ghorban, K. Lower Serum Levels of Meteorin-like/Subfatin in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Are Negatively Associated with Insulin Resistance and Inflammatory Cytokines. PLoS ONE 2018, 13, e0204180. [Google Scholar] [CrossRef]
- El-Ashmawy, H.M.; Selim, F.O.; Hosny, T.A.M.; Almassry, H.N. Association of Low Serum Meteorin like (Metrnl) Concentrations with Worsening of Glucose Tolerance, Impaired Endothelial Function and Atherosclerosis. Diabetes Res. Clin. Pract. 2019, 150, 57–63. [Google Scholar] [CrossRef]
- Lee, J.H.; Kang, Y.E.; Kim, J.M.; Choung, S.; Joung, K.H.; Kim, H.J.; Ku, B.J. Serum Meteorin-like Protein Levels Decreased in Patients Newly Diagnosed with Type 2 Diabetes. Diabetes Res. Clin. Pract. 2018, 135, 7–10. [Google Scholar] [CrossRef] [PubMed]
- Zhang, S.; Li, Z.; Wang, D.; Xu, T.; Fan, M.; Cheng, M.; Miao, C. Aggravated Ulcerative Colitis Caused by Intestinal Metrnl Deficiency Is Associated with Reduced Autophagy in Epithelial Cells. Acta Pharmacol. Sin. 2020, 41, 763–770. [Google Scholar] [CrossRef] [PubMed]
- Qi, Q.; Hu, W.; Zheng, S.; Zhang, S.; Le, Y.; Li, Z.; Miao, C. Metrnl Deficiency Decreases Blood HDL Cholesterol and Increases Blood Triglyceride. Acta Pharmacol. Sin. 2020, 41, 1568–1575. [Google Scholar] [CrossRef] [PubMed]
- Ochieng, J.; Nangami, G.; Sakwe, A.; Moye, C.; Alvarez, J.; Whalen, D.; Thomas, P.; Lammers, P. Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes. Int. J. Mol. Sci. 2018, 19, 2211. [Google Scholar] [CrossRef] [PubMed]
- Artunc, F.; Schleicher, E.; Weigert, C.; Fritsche, A.; Stefan, N.; Häring, H.-U. The Impact of Insulin Resistance on the Kidney and Vasculature. Nat. Rev. Nephrol. 2016, 12, 721–737. [Google Scholar] [CrossRef] [PubMed]
- Miura, Y.; Iwazu, Y.; Shiizaki, K.; Akimoto, T.; Kotani, K.; Kurabayashi, M.; Kurosu, H.; Kuro-o, M. Identification and Quantification of Plasma Calciprotein Particles with Distinct Physical Properties in Patients with Chronic Kidney Disease. Sci. Rep. 2018, 8, 1256. [Google Scholar] [CrossRef] [PubMed]
- Goustin, A.-S.; Abou-Samra, A.B. The “Thrifty” Gene Encoding Ahsg/Fetuin-A Meets the Insulin Receptor: Insights into the Mechanism of Insulin Resistance. Cell. Signal. 2011, 23, 980–990. [Google Scholar] [CrossRef] [PubMed]
- Gerst, F.; Wagner, R.; Kaiser, G.; Panse, M.; Heni, M.; Machann, J.; Bongers, M.N.; Sartorius, T.; Sipos, B.; Fend, F.; et al. Metabolic Crosstalk between Fatty Pancreas and Fatty Liver: Effects on Local Inflammation and Insulin Secretion. Diabetologia 2017, 60, 2240–2251. [Google Scholar] [CrossRef]
- Sujana, C.; Huth, C.; Zierer, A.; Meesters, S.; Sudduth-Klinger, J.; Koenig, W.; Herder, C.; Peters, A.; Thorand, B. Association of Fetuin-A with Incident Type 2 Diabetes: Results from the MONICA/KORA Augsburg Study and a Systematic Meta-Analysis. Eur. J. Endocrinol. 2018, 178, 389–398. [Google Scholar] [CrossRef]
- Guo, V.Y.; Cao, B.; Cai, C.; Cheng, K.K.; Cheung, B.M.Y. Fetuin-A Levels and Risk of Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Acta Diabetol. 2018, 55, 87–98. [Google Scholar] [CrossRef]
- Lanthier, N.; Lebrun, V.; Molendi-Coste, O.; Van Rooijen, N.; Leclercq, I.A. Liver Fetuin-A at Initiation of Insulin Resistance. Metabolites 2022, 12, 1023. [Google Scholar] [CrossRef] [PubMed]
- Sun, Q.; Cornelis, M.C.; Manson, J.E.; Hu, F.B. Plasma Levels of Fetuin-A and Hepatic Enzymes and Risk of Type 2 Diabetes in Women in the U.S. Diabetes 2013, 62, 49–55. [Google Scholar] [CrossRef]
- Trepanowski, J.F.; Mey, J.; Varady, K.A. Fetuin-A: A Novel Link between Obesity and Related Complications. Int. J. Obes. 2015, 39, 734–741. [Google Scholar] [CrossRef] [PubMed]
- Venter, C.; Eyerich, S.; Sarin, T.; Klatt, K.C. Nutrition and the Immune System: A Complicated Tango. Nutrients 2020, 12, 818. [Google Scholar] [CrossRef]
- Erisman, J.W. Nature-Based Agriculture for an Adequate Human Microbiome. Org. Agric. 2021, 11, 225–230. [Google Scholar] [CrossRef]
- Oghbaei, M.; Prakash, J. Effect of Primary Processing of Cereals and Legumes on Its Nutritional Quality: A Comprehensive Review. Cogent Food Agric. 2016, 2, 1136015. [Google Scholar] [CrossRef]
- Whitfield, K.C.; Smith, T.J.; Rohner, F.; Wieringa, F.T.; Green, T.J. Thiamine Fortification Strategies in Low- and Middle-income Settings: A Review. Ann. N. Y. Acad. Sci. 2021, 1498, 29–45. [Google Scholar] [CrossRef]
- Maharaj, P.P.P.; Prasad, S.; Devi, R.; Gopalan, R. Folate Content and Retention in Commonly Consumed Vegetables in the South Pacific. Food Chem. 2015, 182, 327–332. [Google Scholar] [CrossRef]
- Alghamdi, M.; Gutierrez, J.; Komarnytsky, S. Essential Minerals and Metabolic Adaptation of Immune Cells. Nutrients 2022, 15, 123. [Google Scholar] [CrossRef] [PubMed]
- Fiorentini, D.; Cappadone, C.; Farruggia, G.; Prata, C. Magnesium: Biochemistry, Nutrition, Detection, and Social Impact of Diseases Linked to Its Deficiency. Nutrients 2021, 13, 1136. [Google Scholar] [CrossRef]
- Ashique, S.; Kumar, S.; Hussain, A.; Mishra, N.; Garg, A.; Gowda, B.H.J.; Farid, A.; Gupta, G.; Dua, K.; Taghizadeh-Hesary, F. A Narrative Review on the Role of Magnesium in Immune Regulation, Inflammation, Infectious Diseases, and Cancer. J. Health Popul. Nutr. 2023, 42, 74. [Google Scholar] [CrossRef] [PubMed]
- Chu, N.; Chan, T.Y.; Chu, Y.K.; Ling, J.; He, J.; Leung, K.; Ma, R.C.W.; Chan, J.C.N.; Chow, E. Higher Dietary Magnesium and Potassium Intake Are Associated with Lower Body Fat in People with Impaired Glucose Tolerance. Front. Nutr. 2023, 10, 1169705. [Google Scholar] [CrossRef] [PubMed]
- Pelczyńska, M.; Moszak, M.; Bogdański, P. The Role of Magnesium in the Pathogenesis of Metabolic Disorders. Nutrients 2022, 14, 1714. [Google Scholar] [CrossRef] [PubMed]
- Weyh, C.; Krüger, K.; Peeling, P.; Castell, L. The Role of Minerals in the Optimal Functioning of the Immune System. Nutrients 2022, 14, 644. [Google Scholar] [CrossRef] [PubMed]
- Dubey, P.; Thakur, V.; Chattopadhyay, M. Role of Minerals and Trace Elements in Diabetes and Insulin Resistance. Nutrients 2020, 12, 1864. [Google Scholar] [CrossRef] [PubMed]
- Kheriji, N.; Boukhalfa, W.; Mahjoub, F.; Hechmi, M.; Dakhlaoui, T.; Mrad, M.; Hadj Salah Bahlous, A.; Ben Amor, N.; Jamoussi, H.; Kefi, R. The Role of Dietary Intake in Type 2 Diabetes Mellitus: Importance of Macro and Micronutrients in Glucose Homeostasis. Nutrients 2022, 14, 2132. [Google Scholar] [CrossRef]
- Feng, J.; Wang, H.; Jing, Z.; Wang, Y.; Cheng, Y.; Wang, W.; Sun, W. Role of Magnesium in Type 2 Diabetes Mellitus. Biol. Trace Elem. Res. 2020, 196, 74–85. [Google Scholar] [CrossRef] [PubMed]
- Liu, M.; Jeong, E.-M.; Liu, H.; Xie, A.; So, E.Y.; Shi, G.; Jeong, G.E.; Zhou, A.; Dudley, S.C. Magnesium Supplementation Improves Diabetic Mitochondrial and Cardiac Diastolic Function. JCI Insight 2019, 4, e123182. [Google Scholar] [CrossRef]
- Rooney, M.R.; Pankow, J.S.; Sibley, S.D.; Selvin, E.; Reis, J.P.; Michos, E.D.; Lutsey, P.L. Serum Calcium and Incident Type 2 Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study12. Am. J. Clin. Nutr. 2016, 104, 1023–1029. [Google Scholar] [CrossRef]
- Humbert, A.; Lefebvre, R.; Nawrot, M.; Caussy, C.; Rieusset, J. Calcium Signalling in Hepatic Metabolism: Health and Diseases. Cell Calcium 2023, 114, 102780. [Google Scholar] [CrossRef]
- Arruda, A.P.; Hotamisligil, G.S. Calcium Homeostasis and Organelle Function in the Pathogenesis of Obesity and Diabetes. Cell Metab. 2015, 22, 381–397. [Google Scholar] [CrossRef] [PubMed]
- Kim, K.-N.; Oh, S.-Y.; Hong, Y.-C. Associations of Serum Calcium Levels and Dietary Calcium Intake with Incident Type 2 Diabetes over 10 Years: The Korean Genome and Epidemiology Study (KoGES). Diabetol. Metab. Syndr. 2018, 10, 50. [Google Scholar] [CrossRef] [PubMed]
- Park, Y.-J.; Yoo, S.-A.; Kim, M.; Kim, W.-U. The Role of Calcium-Calcineurin-NFAT Signaling Pathway in Health and Autoimmune Diseases. Front. Immunol. 2020, 11, 195. [Google Scholar] [CrossRef] [PubMed]
- Wongdee, K.; Krishnamra, N.; Charoenphandhu, N. Derangement of Calcium Metabolism in Diabetes Mellitus: Negative Outcome from the Synergy between Impaired Bone Turnover and Intestinal Calcium Absorption. J. Physiol. Sci. 2017, 67, 71–81. [Google Scholar] [CrossRef] [PubMed]
- Yanni, A.E.; Kartsioti, K.; Karathanos, V.T. The Role of Yoghurt Consumption in the Management of Type II Diabetes. Food Funct. 2020, 11, 10306–10316. [Google Scholar] [CrossRef] [PubMed]
- Tan, M.; He, F.J.; Wang, C.; MacGregor, G.A. Twenty-Four-Hour Urinary Sodium and Potassium Excretion in China: A Systematic Review and Meta-Analysis. J. Am. Heart Assoc. 2019, 8, e012923. [Google Scholar] [CrossRef] [PubMed]
- Stone, M.S.; Martyn, L.; Weaver, C.M. Potassium Intake, Bioavailability, Hypertension, and Glucose Control. Nutrients 2016, 8, 444. [Google Scholar] [CrossRef] [PubMed]
- Weir, M.R.; Espaillat, R. Clinical Perspectives on the Rationale for Potassium Supplementation. Postgrad. Med. 2015, 127, 539–548. [Google Scholar] [CrossRef] [PubMed]
- Ekmekcioglu, C.; Elmadfa, I.; Meyer, A.L.; Moeslinger, T. The Role of Dietary Potassium in Hypertension and Diabetes. J. Physiol. Biochem. 2016, 72, 93–106. [Google Scholar] [CrossRef]
- Do, E.A.; Gries, C.M. Beyond Homeostasis: Potassium and Pathogenesis during Bacterial Infections. Infect. Immun. 2021, 89, e0076620. [Google Scholar] [CrossRef]
- Chatterjee, R.; Biggs, M.L.; de Boer, I.H.; Brancati, F.L.; Svetkey, L.P.; Barzilay, J.; Djoussé, L.; Ix, J.H.; Kizer, J.R.; Siscovick, D.S.; et al. Potassium and Glucose Measures in Older Adults: The Cardiovascular Health Study. J. Gerontol. Ser. A Biomed. Sci. Med. Sci. 2015, 70, 255–261. [Google Scholar] [CrossRef] [PubMed]
- Brandão-Lima, P.N.; Carvalho, G.B.d.; Santos, R.K.F.; Santos, B.D.C.; Dias-Vasconcelos, N.L.; Rocha, V.D.S.; Barbosa, K.B.F.; Pires, L.V. Intakes of Zinc, Potassium, Calcium, and Magnesium of Individuals with Type 2 Diabetes Mellitus and the Relationship with Glycemic Control. Nutrients 2018, 10, 1948. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.; Ma, H.; Kou, M.; Tang, R.; Xue, Q.; Li, X.; Harlan, T.S.; Heianza, Y.; Qi, L. Dietary Sodium Intake and Risk of Incident Type 2 Diabetes. Mayo Clin. Proc. 2023, 98, 1641–1652. [Google Scholar] [CrossRef] [PubMed]
- Ming, L.; Wang, D.; Zhu, Y. Association of Sodium Intake with Diabetes in Adults without Hypertension: Evidence from the National Health and Nutrition Examination Survey 2009–2018. Front. Public Health 2023, 11, 1118364. [Google Scholar] [CrossRef] [PubMed]
- Schatz, V.; Neubert, P.; Schröder, A.; Binger, K.; Gebhard, M.; Müller, D.N.; Luft, F.C.; Titze, J.; Jantsch, J. Elementary Immunology: Na+ as a Regulator of Immunity. Pediatr. Nephrol. 2017, 32, 201–210. [Google Scholar] [CrossRef]
- Suckling, R.J.; He, F.J.; Markandu, N.D.; MacGregor, G.A. Modest Salt Reduction Lowers Blood Pressure and Albumin Excretion in Impaired Glucose Tolerance and Type 2 Diabetes Mellitus: A Randomized Double-Blind Trial. Hypertension 2016, 67, 1189–1195. [Google Scholar] [CrossRef] [PubMed]
- Calvo, M.S.; Uribarri, J. Public Health Impact of Dietary Phosphorus Excess on Bone and Cardiovascular Health in the General Population. Am. J. Clin. Nutr. 2013, 98, 6–15. [Google Scholar] [CrossRef] [PubMed]
- Mancini, F.R.; Affret, A.; Dow, C.; Balkau, B.; Clavel-Chapelon, F.; Bonnet, F.; Boutron-Ruault, M.-C.; Fagherazzi, G. High Dietary Phosphorus Intake Is Associated with an Increased Risk of Type 2 Diabetes in the Large Prospective E3N Cohort Study. Clin. Nutr. 2018, 37, 1625–1630. [Google Scholar] [CrossRef]
- Hill, C.R.; Shafaei, A.; Balmer, L.; Lewis, J.R.; Hodgson, J.M.; Millar, A.H.; Blekkenhorst, L.C. Sulfur Compounds: From Plants to Humans and Their Role in Chronic Disease Prevention. Crit. Rev. Food Sci. Nutr. 2023, 63, 8616–8638. [Google Scholar] [CrossRef]
- Dong, Z.; Richie, J.P.; Gao, X.; Al-Shaar, L.; Nichenametla, S.N.; Shen, B.; Orentreich, D. Cumulative Consumption of Sulfur Amino Acids and Risk of Diabetes: A Prospective Cohort Study. J. Nutr. 2022, 152, 2419–2428. [Google Scholar] [CrossRef]
- Ke, Q.; Chen, C.; He, F.; Ye, Y.; Bai, X.; Cai, L.; Xia, M. Association between Dietary Protein Intake and Type 2 Diabetes Varies by Dietary Pattern. Diabetol. Metab. Syndr. 2018, 10, 48. [Google Scholar] [CrossRef] [PubMed]
- Tesseraud, S.; Métayer Coustard, S.; Collin, A.; Seiliez, I. Role of Sulfur Amino Acids in Controlling Nutrient Metabolism and Cell Functions: Implications for Nutrition. Br. J. Nutr. 2009, 101, 1132–1139. [Google Scholar] [CrossRef] [PubMed]
- Dong, Z.; Gao, X.; Chinchilli, V.M.; Sinha, R.; Muscat, J.; Winkels, R.M.; Richie, J.P. Association of Sulfur Amino Acid Consumption with Cardiometabolic Risk Factors: Cross-Sectional Findings from NHANES III. eClinicalMedicine 2020, 19, 100248. [Google Scholar] [CrossRef] [PubMed]
- Maywald, M.; Rink, L. Zinc in Human Health and Infectious Diseases. Biomolecules 2022, 12, 1748. [Google Scholar] [CrossRef]
- Davidson, H.W.; Wenzlau, J.M.; O’Brien, R.M. Zinc Transporter 8 (ZnT8) and β Cell Function. Trends Endocrinol. Metab. 2014, 25, 415–424. [Google Scholar] [CrossRef] [PubMed]
- Skalny, A.V.; Aschner, M.; Tinkov, A.A. Zinc. Adv. Food Nutr. Res. 2021, 96, 251–310. [Google Scholar] [CrossRef] [PubMed]
- Wijesekara, N.; Dai, F.F.; Hardy, A.B.; Giglou, P.R.; Bhattacharjee, A.; Koshkin, V.; Chimienti, F.; Gaisano, H.Y.; Rutter, G.A.; Wheeler, M.B. Beta Cell-Specific Znt8 Deletion in Mice Causes Marked Defects in Insulin Processing, Crystallisation and Secretion. Diabetologia 2010, 53, 1656–1668. [Google Scholar] [CrossRef] [PubMed]
- Adulcikas, J.; Sonda, S.; Norouzi, S.; Sohal, S.S.; Myers, S. Targeting the Zinc Transporter ZIP7 in the Treatment of Insulin Resistance and Type 2 Diabetes. Nutrients 2019, 11, 408. [Google Scholar] [CrossRef] [PubMed]
- Zhang, F.; Li, X.; Wei, Y. Selenium and Selenoproteins in Health. Biomolecules 2023, 13, 799. [Google Scholar] [CrossRef]
- Steinbrenner, H.; Duntas, L.H.; Rayman, M.P. The Role of Selenium in Type-2 Diabetes Mellitus and Its Metabolic Comorbidities. Redox Biol. 2022, 50, 102236. [Google Scholar] [CrossRef]
- Kim, J.; Chung, H.S.; Choi, M.K.; Roh, Y.K.; Yoo, H.J.; Park, J.H.; Kim, D.S.; Yu, J.M.; Moon, S. Association between Serum Selenium Level and the Presence of Diabetes Mellitus: A Meta-Analysis of Observational Studies. Diabetes Metab. J. 2019, 43, 447–460. [Google Scholar] [CrossRef] [PubMed]
- Zhou, J.; Huang, K.; Lei, X.G. Selenium and Diabetes—Evidence from Animal Studies. Free. Radic. Biol. Med. 2013, 65, 1548–1556. [Google Scholar] [CrossRef] [PubMed]
- McClung, J.P.; Roneker, C.A.; Mu, W.; Lisk, D.J.; Langlais, P.; Liu, F.; Lei, X.G. Development of Insulin Resistance and Obesity in Mice Overexpressing Cellular Glutathione Peroxidase. Proc. Natl. Acad. Sci. USA 2004, 101, 8852–8857. [Google Scholar] [CrossRef] [PubMed]
- Ni, S.; Yuan, Y.; Kuang, Y.; Li, X. Iron Metabolism and Immune Regulation. Front. Immunol. 2022, 13, 816282. [Google Scholar] [CrossRef]
- Frost, J.N.; Tan, T.K.; Abbas, M.; Wideman, S.K.; Bonadonna, M.; Stoffel, N.U.; Wray, K.; Kronsteiner, B.; Smits, G.; Campagna, D.R.; et al. Hepcidin-Mediated Hypoferremia Disrupts Immune Responses to Vaccination and Infection. Med 2020, 2, 164–179. [Google Scholar] [CrossRef] [PubMed]
- Jabara, H.H.; Boyden, S.E.; Chou, J.; Ramesh, N.; Massaad, M.J.; Benson, H.; Bainter, W.; Fraulino, D.; Rahimov, F.; Sieff, C.; et al. A Missense Mutation in TFRC, Encoding Transferrin Receptor 1, Causes Combined Immunodeficiency. Nat. Genet. 2016, 48, 74–78. [Google Scholar] [CrossRef] [PubMed]
- Harrison, A.V.; Lorenzo, F.R.; McClain, D.A. Iron and the Pathophysiology of Diabetes. Annu. Rev. Physiol. 2023, 85, 339–362. [Google Scholar] [CrossRef] [PubMed]
- Cooksey, R.C.; Jouihan, H.A.; Ajioka, R.S.; Hazel, M.W.; Jones, D.L.; Kushner, J.P.; McClain, D.A. Oxidative Stress, Beta-Cell Apoptosis, and Decreased Insulin Secretory Capacity in Mouse Models of Hemochromatosis. Endocrinology 2004, 145, 5305–5312. [Google Scholar] [CrossRef] [PubMed]
- Liu, J.; Li, Q.; Yang, Y.; Ma, L. Iron Metabolism and Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review. J. Diabetes Investig. 2020, 11, 946–955. [Google Scholar] [CrossRef]
- Zhuang, T.; Han, H.; Yang, Z. Iron, Oxidative Stress and Gestational Diabetes. Nutrients 2014, 6, 3968–3980. [Google Scholar] [CrossRef]
- Basuli, D.; Stevens, R.G.; Torti, F.M.; Torti, S.V. Epidemiological Associations between Iron and Cardiovascular Disease and Diabetes. Front. Pharmacol. 2014, 5, 117. [Google Scholar] [CrossRef] [PubMed]
- Aceves, C.; Mendieta, I.; Anguiano, B.; Delgado-González, E. Molecular Iodine Has Extrathyroidal Effects as an Antioxidant, Differentiator, and Immunomodulator. Int. J. Mol. Sci. 2021, 22, 1228. [Google Scholar] [CrossRef]
- Sun, Z.; Wang, X.; Chen, J.; Duan, P.; Wang, J.; Liu, Y.; Guo, H. Effects of iodine excess on islet β cells(β-TC-6) function and the mechanism. Wei Sheng Yan Jiu 2017, 46, 610–614. [Google Scholar]
- Al-Attas, O.S.; Al-Daghri, N.M.; Alkharfy, K.M.; Alokail, M.S.; Al-Johani, N.J.; Abd-Alrahman, S.H.; Yakout, S.M.; Draz, H.M.; Sabico, S. Urinary Iodine Is Associated with Insulin Resistance in Subjects with Diabetes Mellitus Type 2. Exp. Clin. Endocrinol. Diabetes 2012, 120, 618–622. [Google Scholar] [CrossRef] [PubMed]
- Anil, C.; Akkurt, A.; Ayturk, S.; Kut, A.; Gursoy, A. Impaired Glucose Metabolism Is a Risk Factor for Increased Thyroid Volume and Nodule Prevalence in a Mild-to-Moderate Iodine Deficient Area. Metabolism 2013, 62, 970–975. [Google Scholar] [CrossRef] [PubMed]
- Besold, A.N.; Culbertson, E.M.; Culotta, V.C. The Yin and Yang of Copper during Infection. J. Biol. Inorg. Chem. 2016, 21, 137–144. [Google Scholar] [CrossRef] [PubMed]
- Solomon, E.I.; Heppner, D.E.; Johnston, E.M.; Ginsbach, J.W.; Cirera, J.; Qayyum, M.; Kieber-Emmons, M.T.; Kjaergaard, C.H.; Hadt, R.G.; Tian, L. Copper Active Sites in Biology. Chem. Rev. 2014, 114, 3659–3853. [Google Scholar] [CrossRef]
- Eckersall, P.D.; Saini, P.K.; McComb, C. The Acute Phase Response of Acid Soluble Glycoprotein, Alpha(1)-Acid Glycoprotein, Ceruloplasmin, Haptoglobin and C-Reactive Protein, in the Pig. Vet. Immunol. Immunopathol. 1996, 51, 377–385. [Google Scholar] [CrossRef]
- Raha, S.; Mallick, R.; Basak, S.; Duttaroy, A.K. Is Copper Beneficial for COVID-19 Patients? Med. Hypotheses 2020, 142, 109814. [Google Scholar] [CrossRef]
- Eshak, E.S.; Iso, H.; Maruyama, K.; Muraki, I.; Tamakoshi, A. Associations between Dietary Intakes of Iron, Copper and Zinc with Risk of Type 2 Diabetes Mellitus: A Large Population-Based Prospective Cohort Study. Clin. Nutr. 2018, 37, 667–674. [Google Scholar] [CrossRef]
- Cui, Z.; Zhou, H.; Liu, K.; Wu, M.; Li, S.; Meng, S.; Meng, H. Dietary Copper and Selenium Intakes and the Risk of Type 2 Diabetes Mellitus: Findings from the China Health and Nutrition Survey. Nutrients 2022, 14, 2055. [Google Scholar] [CrossRef] [PubMed]
- Miyazaki, T.; Takenaka, T.; Inoue, T.; Sato, M.; Miyajima, Y.; Nodera, M.; Hanyu, M.; Ohno, Y.; Shibazaki, S.; Suzuki, H. Lipopolysaccharide-Induced Overproduction of Nitric Oxide and Overexpression of iNOS and Interleukin-1β Proteins in Zinc-Deficient Rats. Biol. Trace Elem. Res. 2012, 145, 375–381. [Google Scholar] [CrossRef]
- Eljazzar, S.; Abu-Hijleh, H.; Alkhatib, D.; Sokary, S.; Ismail, S.; Al-Jayyousi, G.F.; Tayyem, R. The Role of Copper Intake in the Development and Management of Type 2 Diabetes: A Systematic Review. Nutrients 2023, 15, 1655. [Google Scholar] [CrossRef] [PubMed]
- Lian, S.; Zhang, T.; Yu, Y.; Zhang, B. Relationship of Circulating Copper Level with Gestational Diabetes Mellitus: A Meta-Analysis and Systemic Review. Biol. Trace Elem. Res. 2021, 199, 4396–4409. [Google Scholar] [CrossRef]
- Leyssens, L.; Vinck, B.; Van Der Straeten, C.; Wuyts, F.; Maes, L. Cobalt Toxicity in Humans-A Review of the Potential Sources and Systemic Health Effects. Toxicology 2017, 387, 43–56. [Google Scholar] [CrossRef]
- Szade, A.; Szade, K.; Nowak, W.N.; Bukowska-Strakova, K.; Muchova, L.; Gońka, M.; Żukowska, M.; Cieśla, M.; Kachamakova-Trojanowska, N.; Rams-Baron, M.; et al. Cobalt Protoporphyrin IX Increases Endogenous G-CSF and Mobilizes HSC and Granulocytes to the Blood. EMBO Mol. Med. 2019, 11, e09571. [Google Scholar] [CrossRef]
- Czarnek, K.; Terpiłowska, S.; Siwicki, A.K. Selected Aspects of the Action of Cobalt Ions in the Human Body. Cent. Eur. J. Immunol. 2015, 40, 236–242. [Google Scholar] [CrossRef] [PubMed]
- Saker, F.; Ybarra, J.; Leahy, P.; Hanson, R.W.; Kalhan, S.C.; Ismail-Beigi, F. Glycemia-Lowering Effect of Cobalt Chloride in the Diabetic Rat: Role of Decreased Gluconeogenesis. Am. J. Physiol. 1998, 274, E984–E991. [Google Scholar] [CrossRef]
- Cao, J.; Vecoli, C.; Neglia, D.; Tavazzi, B.; Lazzarino, G.; Novelli, M.; Masiello, P.; Wang, Y.-T.; Puri, N.; Paolocci, N.; et al. Cobalt-Protoporphyrin Improves Heart Function by Blunting Oxidative Stress and Restoring NO Synthase Equilibrium in an Animal Model of Experimental Diabetes. Front. Physiol. 2012, 3, 160. [Google Scholar] [CrossRef]
- Shrivastava, R.; Upreti, R.K.; Seth, P.K.; Chaturvedi, U.C. Effects of Chromium on the Immune System. FEMS Immunol. Med. Microbiol. 2002, 34, 1–7. [Google Scholar] [CrossRef]
- Anderson, R.A.; Polansky, M.M.; Bryden, N.A.; Roginski, E.E.; Mertz, W.; Glinsmann, W. Chromium Supplementation of Human Subjects: Effects on Glucose, Insulin, and Lipid Variables. Metabolism 1983, 32, 894–899. [Google Scholar] [CrossRef]
- Anderson, R.A. Nutritional Factors Influencing the Glucose/Insulin System: Chromium. J. Am. Coll. Nutr. 1997, 16, 404–410. [Google Scholar] [CrossRef]
- Rajendran, K.; Manikandan, S.; Nair, L.D.; Karuthodiyil, R.; Vijayarajan, N.; Gnanasekar, R.; Kapil, V.V.; Mohamed, A.S. Serum Chromium Levels in Type 2 Diabetic Patients and Its Association with Glycaemic Control. J. Clin. Diagn. Res. 2015, 9, OC05–OC08. [Google Scholar] [CrossRef]
- Horning, K.J.; Caito, S.W.; Tipps, K.G.; Bowman, A.B.; Aschner, M. Manganese Is Essential for Neuronal Health. Annu. Rev. Nutr. 2015, 35, 71–108. [Google Scholar] [CrossRef]
- Waldron, K.J.; Rutherford, J.C.; Ford, D.; Robinson, N.J. Metalloproteins and Metal Sensing. Nature 2009, 460, 823–830. [Google Scholar] [CrossRef]
- Lv, M.; Chen, M.; Zhang, R.; Zhang, W.; Wang, C.; Zhang, Y.; Wei, X.; Guan, Y.; Liu, J.; Feng, K.; et al. Manganese Is Critical for Antitumor Immune Responses via cGAS-STING and Improves the Efficacy of Clinical Immunotherapy. Cell Res. 2020, 30, 966–979. [Google Scholar] [CrossRef]
- Zabłocka-Słowińska, K.; Grajeta, H. The Role of Manganese in Etiopathogenesis and Prevention of Selected Diseases. Adv. Hyg. Exp. Med. 2012, 66, 549–553. [Google Scholar] [CrossRef]
- Anetor, J.I.; Asiribo, O.A.; Adedapo, K.S.; Akingbola, T.S.; Olorunnisola, O.S.; Adeniyi, F.A.A. Increased Plasma Manganese, Partially Reduced Ascorbate, 1 and Absence of Mitochondrial Oxidative Stress in Type 2 Diabetes Mellitus: Implications for the Superoxide Uncoupling Protein 2 (UCP-2) Pathway. Biol. Trace Elem. Res. 2007, 120, 19–27. [Google Scholar] [CrossRef]
- Jomova, K.; Makova, M.; Alomar, S.Y.; Alwasel, S.H.; Nepovimova, E.; Kuca, K.; Rhodes, C.J.; Valko, M. Essential Metals in Health and Disease. Chem. Biol. Interact. 2022, 367, 110173. [Google Scholar] [CrossRef]
- Mendel, R.R. The Molybdenum Cofactor. J. Biol. Chem. 2013, 288, 13165–13172. [Google Scholar] [CrossRef]
- Schwarz, G.; Mendel, R.R.; Ribbe, M.W. Molybdenum Cofactors, Enzymes and Pathways. Nature 2009, 460, 839–847. [Google Scholar] [CrossRef]
- Johannes, L.; Fu, C.-Y.; Schwarz, G. Molybdenum Cofactor Deficiency in Humans. Molecules 2022, 27, 6896. [Google Scholar] [CrossRef]
- Gengelbach, G.P.; Spears, J.W. Effects of Dietary Copper and Molybdenum on Copper Status, Cytokine Production, and Humoral Immune Response of Calves. J. Dairy Sci. 1998, 81, 3286–3292. [Google Scholar] [CrossRef]
- Chen, L.; Liu, J.; Zhang, Y.; Zhang, G.; Kang, Y.; Chen, A.; Feng, X.; Shao, L. The Toxicity of Silica Nanoparticles to the Immune System. Nanomedicine 2018, 13, 1939–1962. [Google Scholar] [CrossRef]
- Mitra, S.; Paul, S.; Roy, S.; Sutradhar, H.; Bin Emran, T.; Nainu, F.; Khandaker, M.U.; Almalki, M.; Wilairatana, P.; Mubarak, M.S. Exploring the Immune-Boosting Functions of Vitamins and Minerals as Nutritional Food Bioactive Compounds: A Comprehensive Review. Molecules 2022, 27, 555. [Google Scholar] [CrossRef]
- Basu, T.K.; Basualdo, C. Vitamin A Homeostasis and Diabetes Mellitus. Nutrition 1997, 13, 804–806. [Google Scholar] [CrossRef]
- Mutlu, A.; Mutlu, G.Y.; Özsu, E.; Çizmecioğlu, F.M.; Hatun, Ş. Vitamin D Deficiency in Children and Adolescents with Type 1 Diabetes. J. Clin. Res. Pediatr. Endocrinol. 2011, 3, 179–183. [Google Scholar] [CrossRef]
- Gupta, S.; Sharma, T.K.; Kaushik, G.G.; Shekhawat, V.P.S. Vitamin E Supplementation May Ameliorate Oxidative Stress in Type 1 Diabetes Mellitus Patients. Clin. Lab. 2011, 57, 379–386. [Google Scholar]
- Bizzaro, G.; Antico, A.; Fortunato, A.; Bizzaro, N. Vitamin D and Autoimmune Diseases: Is Vitamin D Receptor (VDR) Polymorphism the Culprit? Isr. Med. Assoc. J. 2017, 19, 438–443. [Google Scholar]
- White, J.H. Vitamin D Metabolism and Signaling in the Immune System. Rev. Endocr. Metab. Disord. 2012, 13, 21–29. [Google Scholar] [CrossRef]
- Sîrbe, C.; Rednic, S.; Grama, A.; Pop, T.L. An Update on the Effects of Vitamin D on the Immune System and Autoimmune Diseases. Int. J. Mol. Sci. 2022, 23, 9784. [Google Scholar] [CrossRef]
- Piemonti, L.; Monti, P.; Sironi, M.; Fraticelli, P.; Leone, B.E.; Dal Cin, E.; Allavena, P.; Di Carlo, V. Vitamin D3 Affects Differentiation, Maturation, and Function of Human Monocyte-Derived Dendritic Cells. J. Immunol. 2000, 164, 4443–4451. [Google Scholar] [CrossRef]
- Penna, G.; Adorini, L. 1 Alpha,25-Dihydroxyvitamin D3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation. J. Immunol. 2000, 164, 2405–2411. [Google Scholar] [CrossRef]
- Bastos, T.S.B.; Braga, T.T.; Davanso, M.R. Vitamin D and Omega-3 Polyunsaturated Fatty Acids in Type 1 Diabetes Modulation. Endocr. Metab. Immune Disord. Drug Targets 2022, 22, 815–833. [Google Scholar] [CrossRef]
- Habibian, N.; Amoli, M.M.; Abbasi, F.; Rabbani, A.; Alipour, A.; Sayarifard, F.; Rostami, P.; Dizaji, S.P.; Saadati, B.; Setoodeh, A. Role of Vitamin D and Vitamin D Receptor Gene Polymorphisms on Residual Beta Cell Function in Children with Type 1 Diabetes Mellitus. Pharmacol. Rep. 2019, 71, 282–288. [Google Scholar] [CrossRef]
- Wu, J.; Atkins, A.; Downes, M.; Wei, Z. Vitamin D in Diabetes: Uncovering the Sunshine Hormone’s Role in Glucose Metabolism and Beyond. Nutrients 2023, 15, 1997. [Google Scholar] [CrossRef]
- Yu, J.; Sharma, P.; Girgis, C.M.; Gunton, J.E. Vitamin D and Beta Cells in Type 1 Diabetes: A Systematic Review. Int. J. Mol. Sci. 2022, 23, 14434. [Google Scholar] [CrossRef]
- Hafez, M.; Musa, N.; Abdel Atty, S.; Ibrahem, M.; Abdel Wahab, N. Effect of Vitamin D Supplementation on Lipid Profile in Vitamin D-Deficient Children with Type 1 Diabetes and Dyslipidemia. Horm. Res. Paediatr. 2019, 91, 311–318. [Google Scholar] [CrossRef]
- Sacerdote, A.; Dave, P.; Lokshin, V.; Bahtiyar, G. Type 2 Diabetes Mellitus, Insulin Resistance, and Vitamin D. Curr. Diabetes Rep. 2019, 19, 101. [Google Scholar] [CrossRef]
- Brigelius-Flohé, R.; Traber, M.G. Vitamin E: Function and Metabolism. FASEB J. 1999, 13, 1145–1155. [Google Scholar] [CrossRef]
- Birringer, M.; Lorkowski, S. Vitamin E: Regulatory Role of Metabolites. IUBMB Life 2019, 71, 479–486. [Google Scholar] [CrossRef]
- Jin, Z.; Sun, J.; Zhang, W. Effect of Vitamin E on Diabetic Nephropathy: A Meta-Analysis. Altern. Ther. Health Med. 2024; online ahead of print. [Google Scholar]
- Mehvari, F.; Imanparast, F.; Mohaghegh, P.; Alimoradian, A.; Khansari, N.; Ansari Asl, B.; Khosrowbeygi, A. Correction: Protective Effects of Paraoxonase-1, Vitamin E and Selenium, and Oxidative Stress Index on the Susceptibility of Low Density Lipoprotein to Oxidation in Diabetic Patients with/without Coronary Artery Disease. Eur. J. Med. Res. 2023, 28, 459. [Google Scholar] [CrossRef]
- Carr, A.C.; Maggini, S. Vitamin C and Immune Function. Nutrients 2017, 9, 1211. [Google Scholar] [CrossRef]
- Badawi, A.; Klip, A.; Haddad, P.; Cole, D.E.; Bailo, B.G.; El-Sohemy, A.; Karmali, M. Type 2 Diabetes Mellitus and Inflammation: Prospects for Biomarkers of Risk and Nutritional Intervention. Diabetes Metab. Syndr. Obes. Targets Ther. 2010, 3, 173–186. [Google Scholar] [CrossRef]
- Grzebyk, E.; Piwowar, A. Inhibitory Actions of Selected Natural Substances on Formation of Advanced Glycation Endproducts and Advanced Oxidation Protein Products. BMC Complement. Altern. Med. 2016, 16, 381. [Google Scholar] [CrossRef]
- Afkhami-Ardekani, M.; Shojaoddiny-Ardekani, A. Effect of Vitamin C on Blood Glucose, Serum Lipids & Serum Insulin in Type 2 Diabetes Patients. Indian J. Med. Res. 2007, 126, 471–474. [Google Scholar]
- Frank, L.L. Thiamin in Clinical Practice. J. Parenter. Enter. Nutr. 2015, 39, 503–520. [Google Scholar] [CrossRef]
- Muley, A.; Fernandez, R.; Green, H.; Muley, P. Effect of Thiamine Supplementation on Glycaemic Outcomes in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis. BMJ Open 2022, 12, e059834. [Google Scholar] [CrossRef] [PubMed]
- Mascolo, E.; Vernì, F. Vitamin B6 and Diabetes: Relationship and Molecular Mechanisms. Int. J. Mol. Sci. 2020, 21, 3669. [Google Scholar] [CrossRef]
- Cigolini, M.; Iagulli, M.P.; Miconi, V.; Lorenzi, T.; Lombardi, S.; Targher, G. Inflammatory Variables May Mediate the Link between Low Plasma Vitamin B6 Concentrations and Cardiovascular Disease in Type 2 Diabetes. Nutr. Metab. Cardiovasc. Dis. 2006, 16, e9–e10. [Google Scholar] [CrossRef]
- Halczuk, K.; Kaźmierczak-Barańska, J.; Karwowski, B.T.; Karmańska, A.; Cieślak, M. Vitamin B12-Multifaceted In Vivo Functions and In Vitro Applications. Nutrients 2023, 15, 2734. [Google Scholar] [CrossRef] [PubMed]
- Reynolds, E. Vitamin B12, Folic Acid, and the Nervous System. Lancet Neurol. 2006, 5, 949–960. [Google Scholar] [CrossRef] [PubMed]
- Yadav, A.; Jyoti, S.; Mehta, R.K.; Parajuli, S.B. Vitamin B12 Deficiency among Metformin Treated Type 2 Diabetic Mellitus Patients Visiting the Department of Medicine of a Tertiary Care Centre. J. Nepal Med. Assoc. 2023, 61, 861–863. [Google Scholar] [CrossRef] [PubMed]
- Tiwari, A.; Kumar Singh, R.; Satone, P.D.; Meshram, R.J. Metformin-Induced Vitamin B12 Deficiency in Patients with Type-2 Diabetes Mellitus. Cureus 2023, 15, e47771. [Google Scholar] [CrossRef] [PubMed]
- Valdés-Ramos, R.; Guadarrama-López, A.L.; Martínez-Carrillo, B.E.; Benítez-Arciniega, A.D. Vitamins and Type 2 Diabetes Mellitus. Endocr. Metab. Immune Disord. Drug Targets 2015, 15, 54–63. [Google Scholar] [CrossRef] [PubMed]
- Elmadfa, I.; Meyer, A.L. The Role of the Status of Selected Micronutrients in Shaping the Immune Function. Endocr. Metab. Immune Disord. Drug Targets 2019, 19, 1100–1115. [Google Scholar] [CrossRef]
- Title, L.M.; Ur, E.; Giddens, K.; McQueen, M.J.; Nassar, B.A. Folic Acid Improves Endothelial Dysfunction in Type 2 Diabetes—An Effect Independent of Homocysteine-Lowering. Vasc. Med. 2006, 11, 101–109. [Google Scholar] [CrossRef]
- Alian, Z.; Hashemipour, M.; Dehkordi, E.H.; Hovsepian, S.; Amini, M.; Moadab, M.H.; Javanmard, S.H. The Effects of Folic Acid on Markers of Endothelial Function in Patients with Type 1 Diabetes Mellitus. Med. Arch. 2012, 66, 12–15. [Google Scholar] [CrossRef]
- Asbaghi, O.; Ashtary-Larky, D.; Bagheri, R.; Moosavian, S.P.; Olyaei, H.P.; Nazarian, B.; Rezaei Kelishadi, M.; Wong, A.; Candow, D.G.; Dutheil, F.; et al. Folic Acid Supplementation Improves Glycemic Control for Diabetes Prevention and Management: A Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials. Nutrients 2021, 13, 2355. [Google Scholar] [CrossRef] [PubMed]
- Fatahi, S.; Pezeshki, M.; Mousavi, S.M.; Teymouri, A.; Rahmani, J.; Kord Varkaneh, H.; Ghaedi, E. Effects of Folic Acid Supplementation on C-Reactive Protein: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutr. Metab. Cardiovasc. Dis. 2019, 29, 432–439. [Google Scholar] [CrossRef]
- Brownlee, M. The Pathobiology of Diabetic Complications. Diabetes 2005, 54, 1615–1625. [Google Scholar] [CrossRef] [PubMed]
- Wright, E.; Scism-Bacon, J.L.; Glass, L.C. Oxidative Stress in Type 2 Diabetes: The Role of Fasting and Postprandial Glycaemia: Oxidative Stress in Type 2 Diabetes. Int. J. Clin. Pract. 2006, 60, 308–314. [Google Scholar] [CrossRef] [PubMed]
- Papachristoforou, E.; Lambadiari, V.; Maratou, E.; Makrilakis, K. Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications. J. Diabetes Res. 2020, 2020, 7489795. [Google Scholar] [CrossRef] [PubMed]
- Shen, Q.; Pierce, J. Supplementation of Coenzyme Q10 among Patients with Type 2 Diabetes Mellitus. Healthcare 2015, 3, 296–309. [Google Scholar] [CrossRef] [PubMed]
- Renke, G.; Pereira, M.B.; Renke, A. Coenzyme Q10 for Diabetes and Cardiovascular Disease: Useful or Useless? Curr. Diabetes Rev. 2023, 19, e290422204261. [Google Scholar] [CrossRef] [PubMed]
- Weber, C.; Bysted, A.; Hølmer, G. Coenzyme Q10 in the Diet-Daily Intake and Relative Bioavailability. Mol. Asp. Med. 1997, 18, 251–254. [Google Scholar] [CrossRef] [PubMed]
- Bhagavan, H.N.; Chopra, R.K. Coenzyme Q10: Absorption, Tissue Uptake, Metabolism and Pharmacokinetics. Free Radic. Res. 2006, 40, 445–453. [Google Scholar] [CrossRef] [PubMed]
- El-ghoroury, E.A.; Raslan, H.M.; Badawy, E.A.; El-Saaid, G.S.; Agybi, M.H.; Siam, I.; Salem, S.I. Malondialdehyde and Coenzyme Q10 in Platelets and Serum in Type 2 Diabetes Mellitus: Correlation with Glycemic Control. Blood Coagul. Fibrinolysis 2009, 20, 248. [Google Scholar] [CrossRef]
- Hodgson, J.; Watts, G.; Playford, D.; Burke, V.; Croft, K. Coenzyme Q10 Improves Blood Pressure and Glycaemic Control: A Controlled Trial in Subjects with Type 2 Diabetes. Eur. J. Clin. Nutr. 2002, 56, 1137–1142. [Google Scholar] [CrossRef]
- Mehrdadi, P.; Kolahdouz Mohammadi, R.; Alipoor, E.; Eshraghian, M.; Esteghamati, A.; Hosseinzadeh-Attar, M. The Effect of Coenzyme Q10 Supplementation on Circulating Levels of Novel Adipokine Adipolin/CTRP12 in Overweight and Obese Patients with Type 2 Diabetes. Exp. Clin. Endocrinol. Diabetes 2016, 125, 156–162. [Google Scholar] [CrossRef]
- Yen, C.-H.; Chu, Y.-J.; Lee, B.-J.; Lin, Y.-C.; Lin, P.-T. Effect of Liquid Ubiquinol Supplementation on Glucose, Lipids and Antioxidant Capacity in Type 2 Diabetes Patients: A Double-Blind, Randomised, Placebo-Controlled Trial. Br. J. Nutr. 2018, 120, 57–63. [Google Scholar] [CrossRef] [PubMed]
- Liang, Y.; Zhao, D.; Ji, Q.; Liu, M.; Dai, S.; Hou, S.; Liu, Z.; Mao, Y.; Tian, Z.; Yang, Y. Effects of Coenzyme Q10 Supplementation on Glycemic Control: A GRADE-Assessed Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials. eClinicalMedicine 2022, 52, 101602. [Google Scholar] [CrossRef]
- Chew, G.T.; Watts, G.F. Coenzyme Q10 and Diabetic Endotheliopathy: Oxidative Stress and the “Recoupling Hypothesis”. QJM 2004, 97, 537–548. [Google Scholar] [CrossRef] [PubMed]
- Hamilton, S.J.; Chew, G.T.; Watts, G.F. Coenzyme Q10 Improves Endothelial Dysfunction in Statin-Treated Type 2 Diabetic Patients. Diabetes Care 2009, 32, 810–812. [Google Scholar] [CrossRef]
- Mortensen, S.A.; Rosenfeldt, F.; Kumar, A.; Dolliner, P.; Filipiak, K.J.; Pella, D.; Alehagen, U.; Steurer, G.; Littarru, G.P. The Effect of Coenzyme Q10 on Morbidity and Mortality in Chronic Heart Failure: Results from Q-SYMBIO: A Randomized Double-Blind Trial. JACC Heart Fail. 2014, 2, 641–649. [Google Scholar] [CrossRef]
- Hernández-Ojeda, J.; Cardona-Muñoz, E.G.; Román-Pintos, L.M.; Troyo-Sanromán, R.; Ortiz-Lazareno, P.C.; Cárdenas-Meza, M.A.; Pascoe-González, S.; Miranda-Díaz, A.G. The Effect of Ubiquinone in Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study. J. Diabetes Complicat. 2012, 26, 352–358. [Google Scholar] [CrossRef] [PubMed]
- Reed, L.J.; DeBUSK, B.G.; Gunsalus, I.C.; Hornberger, C.S. Crystalline Alpha-Lipoic Acid; a Catalytic Agent Associated with Pyruvate Dehydrogenase. Science 1951, 114, 93–94. [Google Scholar] [CrossRef]
- Brookes, M.H.; Golding, B.T.; Howes, D.A.; Hudson, A.T. Proof That the Absolute Configuration of Natural α-Lipoic Acid Is R by the Synthesis of Its Enantiomer [(S)-(–)-α-Lipoic Acid] from (S)-Malic Acid. J. Chem. Soc. Chem. Commun. 1983, 1051–1053. [Google Scholar] [CrossRef]
- Ghibu, S.; Richard, C.; Vergely, C.; Zeller, M.; Cottin, Y.; Rochette, L. Antioxidant Properties of an Endogenous Thiol: Alpha-Lipoic Acid, Useful in the Prevention of Cardiovascular Diseases. J. Cardiovasc. Pharmacol. 2009, 54, 391–398. [Google Scholar] [CrossRef]
- Salehi, B.; Yılmaz, Y.B.; Antika, G.; Tumer, T.B.; Mahomoodally, M.F.; Lobine, D.; Akram, M.; Riaz, M.; Capanoglu, E.; Sharopov, F.; et al. Insights on the Use of α-Lipoic Acid for Therapeutic Purposes. Biomolecules 2019, 9, 356. [Google Scholar] [CrossRef]
- Lodge, J.K.; Youn, H.D.; Handelman, G.J.; Konishi, T.; Matsugo, S.; Mathur, V.V.; Packer, L. Natural Sources of Lipoic Acid: Determination of Lipoyllysine Released from Protease-Digested Tissues by High Performance Liquid Chromatography Incorporating Electrochemical Detection. J. Appl. Nutr. 1997, 49, 3–11. [Google Scholar]
- Schupke, H.; Hempel, R.; Peter, G.; Hermann, R.; Wessel, K.; Engel, J.; Kronbach, T. New Metabolic Pathways of Alpha-Lipoic Acid. Drug Metab. Dispos. Biol. Fate Chem. 2001, 29, 855–862. [Google Scholar]
- Gomes, M.B.; Negrato, C.A. Alpha-Lipoic Acid as a Pleiotropic Compound with Potential Therapeutic Use in Diabetes and Other Chronic Diseases. Diabetol. Metab. Syndr. 2014, 6, 80. [Google Scholar] [CrossRef] [PubMed]
- Golbidi, S.; Badran, M.; Laher, I. Diabetes and Alpha Lipoic Acid. Front. Pharmacol. 2011, 2, 69. [Google Scholar] [CrossRef]
- Brasier, A.R. The NF-kappaB Regulatory Network. Cardiovasc. Toxicol. 2006, 6, 111–130. [Google Scholar] [CrossRef]
- Vlahopoulos, S.A. Aberrant Control of NF-κB in Cancer Permits Transcriptional and Phenotypic Plasticity, to Curtail Dependence on Host Tissue: Molecular Mode. Cancer Biol. Med. 2017, 14, 254–270. [Google Scholar] [CrossRef] [PubMed]
- Bacher, S.; Schmitz, M.L. The NF-kappaB Pathway as a Potential Target for Autoimmune Disease Therapy. Curr. Pharm. Des. 2004, 10, 2827–2837. [Google Scholar] [CrossRef] [PubMed]
- Kauppinen, A.; Suuronen, T.; Ojala, J.; Kaarniranta, K.; Salminen, A. Antagonistic Crosstalk between NF-κB and SIRT1 in the Regulation of Inflammation and Metabolic Disorders. Cell. Signal. 2013, 25, 1939–1948. [Google Scholar] [CrossRef]
- Bashan, N.; Kovsan, J.; Kachko, I.; Ovadia, H.; Rudich, A. Positive and Negative Regulation of Insulin Signaling by Reactive Oxygen and Nitrogen Species. Physiol. Rev. 2009, 89, 27–71. [Google Scholar] [CrossRef]
- Boullier, A.; Bird, D.A.; Chang, M.K.; Dennis, E.A.; Friedman, P.; Gillotre-Taylor, K.; Hörkkö, S.; Palinski, W.; Quehenberger, O.; Shaw, P.; et al. Scavenger Receptors, Oxidized LDL, and Atherosclerosis. Ann. N. Y. Acad. Sci. 2001, 947, 214–222, discussion 222–223. [Google Scholar] [CrossRef]
- Taniyama, Y.; Griendling, K.K. Reactive Oxygen Species in the Vasculature: Molecular and Cellular Mechanisms. Hypertension 2003, 42, 1075–1081. [Google Scholar] [CrossRef]
- Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; et al. Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action. J. Clin. Investig. 2001, 108, 1167–1174. [Google Scholar] [CrossRef]
- Kim, M.-S.; Park, J.-Y.; Namkoong, C.; Jang, P.-G.; Ryu, J.-W.; Song, H.-S.; Yun, J.-Y.; Namgoong, I.-S.; Ha, J.; Park, I.-S.; et al. Anti-Obesity Effects of Alpha-Lipoic Acid Mediated by Suppression of Hypothalamic AMP-Activated Protein Kinase. Nat. Med. 2004, 10, 727–733. [Google Scholar] [CrossRef]
- Ruze, R.; Liu, T.; Zou, X.; Song, J.; Chen, Y.; Xu, R.; Yin, X.; Xu, Q. Obesity and Type 2 Diabetes Mellitus: Connections in Epidemiology, Pathogenesis, and Treatments. Front. Endocrinol. 2023, 14, 1161521. [Google Scholar] [CrossRef]
- Packer, L.; Kraemer, K.; Rimbach, G. Molecular Aspects of Lipoic Acid in the Prevention of Diabetes Complications. Nutrition 2001, 17, 888–895. [Google Scholar] [CrossRef]
- Watanabe, Y.; Tatsuno, I. Prevention of Cardiovascular Events with Omega-3 Polyunsaturated Fatty Acids and the Mechanism Involved. J. Atheroscler. Thromb. 2020, 27, 183–198. [Google Scholar] [CrossRef]
- Lorente-Cebrián, S.; Costa, A.G.V.; Navas-Carretero, S.; Zabala, M.; Martínez, J.A.; Moreno-Aliaga, M.J. Role of Omega-3 Fatty Acids in Obesity, Metabolic Syndrome, and Cardiovascular Diseases: A Review of the Evidence. J. Physiol. Biochem. 2013, 69, 633–651. [Google Scholar] [CrossRef]
- Egalini, F.; Guardamagna, O.; Gaggero, G.; Varaldo, E.; Giannone, B.; Beccuti, G.; Benso, A.; Broglio, F. The Effects of Omega 3 and Omega 6 Fatty Acids on Glucose Metabolism: An Updated Review. Nutrients 2023, 15, 2672. [Google Scholar] [CrossRef]
- Doaei, S.; Gholami, S.; Rastgoo, S.; Gholamalizadeh, M.; Bourbour, F.; Bagheri, S.E.; Samipoor, F.; Akbari, M.E.; Shadnoush, M.; Ghorat, F.; et al. The Effect of Omega-3 Fatty Acid Supplementation on Clinical and Biochemical Parameters of Critically Ill Patients with COVID-19: A Randomized Clinical Trial. J. Transl. Med. 2021, 19, 128. [Google Scholar] [CrossRef]
- Bhaswant, M.; Poudyal, H.; Brown, L. Mechanisms of Enhanced Insulin Secretion and Sensitivity with N-3 Unsaturated Fatty Acids. J. Nutr. Biochem. 2015, 26, 571–584. [Google Scholar] [CrossRef]
- Qian, F.; Korat, A.V.A.; Imamura, F.; Marklund, M.; Tintle, N.; Virtanen, J.K.; Zhou, X.; Bassett, J.K.; Lai, H.; Hirakawa, Y.; et al. N-3 Fatty Acid Biomarkers and Incident Type 2 Diabetes: An Individual Participant-Level Pooling Project of 20 Prospective Cohort Studies. Diabetes Care 2021, 44, 1133–1142. [Google Scholar] [CrossRef] [PubMed]
- Zhang, K.; Qin, W.; Zheng, Y.; Pang, J.; Zhong, N.; Fei, J.; Li, Y.; Jian, X.; Hou, X.; Hu, Z.; et al. Malnutrition Contributes to Low Lymphocyte Count in Early-Stage Coronavirus Disease-2019. Front. Nutr. 2021, 8, 739216. [Google Scholar] [CrossRef]
- Pilar Vaquero, M.; Martínez-Suárez, M.; García-Quismondo, Á.; Del Cañizo, F.J.; Sánchez-Muniz, F.J. Diabesity Negatively Affects Transferrin Saturation and Iron Status. The DICARIVA Study. Diabetes Res. Clin. Pract. 2021, 172, 108653. [Google Scholar] [CrossRef]
- Napiórkowska-Baran, K.; Ziętkiewicz, M.; Więsik-Szewczyk, E.; Matyja-Bednarczyk, A.; Tykwińska, M.; Alska, E.; Rosada, T.; Szynkiewicz, E.; Lubański, J.; Schmidt, O.; et al. Points to Consider in Health Assessment of Adult Patients with Primary Antibody Deficiencies. J. Clin. Med. 2023, 12, 6018. [Google Scholar] [CrossRef]
Antidiabetic Drug | Mechanism of Action | Function |
---|---|---|
Tirzepatide | Dual agonist of GIP and GLP-1 receptors |
|
Pioglitazone | PPARγ agonist |
|
DA-1241 | GPR119 receptor agonist |
|
Vaspin | Kallikrein 7 inhibitor |
|
Metrnl | PPARγ receptor agonist |
|
Fetuin-A | The extracellular portion of the transmembrane β-subunit of the insulin receptor (InsR) |
|
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Napiórkowska-Baran, K.; Treichel, P.; Czarnowska, M.; Drozd, M.; Koperska, K.; Węglarz, A.; Schmidt, O.; Darwish, S.; Szymczak, B.; Bartuzi, Z. Immunomodulation through Nutrition Should Be a Key Trend in Type 2 Diabetes Treatment. Int. J. Mol. Sci. 2024, 25, 3769. https://doi.org/10.3390/ijms25073769
Napiórkowska-Baran K, Treichel P, Czarnowska M, Drozd M, Koperska K, Węglarz A, Schmidt O, Darwish S, Szymczak B, Bartuzi Z. Immunomodulation through Nutrition Should Be a Key Trend in Type 2 Diabetes Treatment. International Journal of Molecular Sciences. 2024; 25(7):3769. https://doi.org/10.3390/ijms25073769
Chicago/Turabian StyleNapiórkowska-Baran, Katarzyna, Paweł Treichel, Marta Czarnowska, Magdalena Drozd, Kinga Koperska, Agata Węglarz, Oskar Schmidt, Samira Darwish, Bartłomiej Szymczak, and Zbigniew Bartuzi. 2024. "Immunomodulation through Nutrition Should Be a Key Trend in Type 2 Diabetes Treatment" International Journal of Molecular Sciences 25, no. 7: 3769. https://doi.org/10.3390/ijms25073769